- MASH affects 6% of US adults - Linked to liver cancer, transplant risk, and cardiometabolic complications - First approved therapy targeting both metabolic dysfunction and fibrotic progression Clinical Implications - Early intervention now has a validated pharmacologic option - Opens doors for multidisciplinary care across hepatology, endocrinology, and primary care - Reinforces the role of GLP-1 therapies beyond diabetes and obesity Your Voice Matters: How will semaglutides approval reshape your approach to managing MASH and liver fibrosisespecially in high-risk or underserved populations
Among the mechanisms underlying these traits, quiescence, drug efflux transporters, ALDH activity, apoptosis resistance, and metabolic reprogramming are particularly well characterized 327,328 (Fig
L.MehtaA.RosensonR
Talk with a clinician about your goals, plateaus, and any concerning patterns
Because of this phenomenon, older animal models were an ideal subject group for studying potential improvements brought about by paraxanthine supplementation." "However," he continued, "in younger individuals, cognition is already at its best, so seeing significant improvements to an already well-functioning system is quite surprising." This finding highlights the potential of paraxanthine as a caffeine replacement in individuals of all ages, suggesting that it may be better suited to cognition-focused supplement formulations
Karagulle 2007)
